Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA

Seywright, A., Torrance, H. J. , Wylie, F. M., Mckeown, D. A., Lowe, D. J. and Stevenson, R. (2016) Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clinical Toxicology, 54(8), pp. 632-637. (doi: 10.1080/15563650.2016.1186805) (PMID:27213960)

[img]
Preview
Text
119581.pdf - Accepted Version

632kB

Abstract

Context: MDMB-CHMICA is a synthetic cannabinoid receptor agonist which has caused concern due to its presence in cases of adverse reaction and death. Method: 43 cases of suspected synthetic cannabinoid ingestion were identified from patients presenting at an Emergency Department and from post-mortem casework. These were subjected to liquid-liquid extraction using tertiary-butyl methyl ether and quantitatively analysed by Electospray Ionisation Liquid Chromatography – tandem Mass Spectrometry. For positive samples, case and clinical details were sought and interrogated. Results: 11 samples were found positive for MDMB-CHMICA. Concentrations found ranged from <1 – 22 ng/mL (mean: 6 ng/mL, median: 3 ng/mL). The age range was 15 – 44 years (mean: 26 years, median: 21 years), with the majority (82%) of positive results found in males. Clinical presentations included hypothermia, hypoglycaemia, syncope, recurrent vomiting, altered mental state and serotonin toxicity, with corresponding concentrations of MDMB-CHMICA as low as <1 ng/mL. Duration of hospitalisation ranged from 3 – 24 hours (mean: 12 hours, median: 8 hours). Discussion: The concentration range presented in this case series is indicative of MDMB-CHMICA having a high potency, as is known to be the case for other synthetic cannabinoid receptor agonists. The age range and gender representation were consistent with that reported for users of other drugs of this type. The clinical presentations observed were typical of synthetic cannabinoid receptor agonists and show the difficulties in identifying reactions potentially associated with drugs of this type. Conclusion: The range of MDMB-CHMICA concentrations in Emergency Department presentations (n=9) and post-mortem cases (n=2) was reported. No correlation between the concentration of this drug and clinical presentation or cause of death was reported in this sample. However, the potential for harm associated with low concentrations of MDMB-CHMICA and the symptoms of toxicity being non-specific was highlighted.

Item Type:Articles
Additional Information:A contribution to funding was made by the Scottish Government.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Wylie, Dr Fiona and Lowe, Dr David and Seywright, Mrs Alice and Torrance, Dr Hazel and Mckeown, Miss Denise
Authors: Seywright, A., Torrance, H. J., Wylie, F. M., Mckeown, D. A., Lowe, D. J., and Stevenson, R.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Clinical Toxicology
Publisher:Taylor & Francis
ISSN:1556-3650
ISSN (Online):1556-9519
Published Online:23 May 2016
Copyright Holders:Copyright © 2016 Taylor and Francis
First Published:First published in Clinical Toxicology 54(8):632-637
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record